hypercholesterolemia
Conditions
Interventions
Oral administration of pitavastatin(2 mg/day) for a year. The dosage may be modulated according to the clinical parameters (pitavastatin 1 - 4 mg).
Sponsors
Ogaki Municipal Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who were diagnosed as hypercholesterolemia based in Japan Atherosclerosis Society guidelines for prevention of atherosclerotic cardiovascular diseases.
Exclusion criteria
Exclusion criteria: 1) HDL-C more than 100mg/dL. 2) Severe hypertensive patients. 3) History of cerebrovascular disease in 3 months before registration. 4) Severe renal dysfunction (creatinine>=2.0mg/dL) 5) Severe hepatic dysfunction. 6) Collagen disease. 7) Pregnant women, women suspected of being pregnant and lactating women or patients aiming to become pregnant during the clinical trial. 8) Without written informed consent. 9) Patients who are ineligible in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between %change of high-density lipoprotein cholesterol and regression of carotid artery plaque. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Correlation between %change of LDL-C/ApoA1/hsCRP and regression of carotid artery plaque. 2. Incidence of major adverse cardiovascular events (MACE; defined as cardiac death, nonfatal myocardial infarction, unstable angina/cardiac failure/stroke / any other cardiac events required hospitalization). 3. Incidence of adverse effects. | — |
Countries
Japan
Outcome results
None listed